Summit Therapeutics's market cap is currently $15.55B. The company's EPS TTM is $-0.276; its P/E ratio is ―; Summit Therapeutics is scheduled to report earnings on March 13, 2025, and the estimated EPS forecast is $-0.08. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 0.00	$ 704.29K	$ 1.81M	$ 860.00K	-
Gross Profit	$ -2.05M	$ -1.81M	$ 1.81M	$ 860.00K	-
Operating Income	$ -89.74M	$ -72.09M	$ -86.19M	$ -53.19M	$ -42.76M
EBITDA	$ 1.00M	$ -52.63M	$ -62.74M	$ -37.13M	$ -16.80M
Net Income	$ -614.93M	$ -74.38M	$ -86.15M	$ -52.70M	$ -23.88M
Balance Sheet
Cash & Short-Term Investments	$ 186.24M	$ 348.61M	$ 71.79M	$ 66.42M	$ 49.96M
Total Assets	$ 202.95M	$ 664.17M	$ 113.37M	$ 102.50M	$ 75.46M
Total Debt	$ 106.10M	$ 518.76M	$ 2.78M	$ 465.00K	-
Net Debt	$ 34.67M	$ 170.16M	$ -69.01M	$ -65.95M	$ -49.26M
Total Liabilities	$ 125.26M	$ 537.51M	$ 30.09M	$ 23.05M	$ 14.34M
Stockholders' Equity	$ 77.69M	$ 126.65M	$ 83.28M	$ 79.45M	$ 61.12M
Cash Flow
Free Cash Flow	$ -76.89M	$ -42.21M	$ -72.89M	$ -48.53M	$ -15.83M
Operating Cash Flow	$ -76.76M	$ -41.58M	$ -72.59M	$ -48.11M	$ -15.56M
Investing Cash Flow	$ -587.77M	$ -624.00K	$ -306.00K	$ -421.00K	-
Financing Cash Flow	$ 86.51M	$ 620.24M	$ 77.92M	$ 50.55M	$ 37.46M

Currency in USD

Summit Therapeutics Earnings and Revenue History

Income Statement >

Summit Therapeutics Debt to Assets

Balance Sheet >

Summit Therapeutics Cash Flow

Cash Flow >

Summit Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing